Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: Results from a randomized, placebo-controlled trial  by Rahe-Meyer, Niels et al.
Panel 4 Rahe-Meyer et alFibrinogen concentrate reduces intraoperative bleeding when used
as first-line hemostatic therapy during major aortic replacement
surgery: Results from a randomized, placebo-controlled trialNiels Rahe-Meyer, MD, MSc, PhD,a,b Alexander Hanke, MD,b Dirk S. Schmidt, PhD,c
Christian Hagl, MD,d,e and Maximilian Pichlmaier, MDdFrom th
tal, B
Hann
many
Medi
Clinic
Funding
partic
data c
full ac
assist
Disclosu
fundin
pated
CSL
Behri
Read at
New
Receive
public
Address
and In
feld,
0022-52
Copyrig
for Thor
http://dx
S178Objectives: We assessed whether fibrinogen concentrate as targeted first-line hemostatic therapy was more
effective than placebo or a standardized transfusion algorithm in controlling coagulopathic bleeding in patients
undergoing major aortic surgery.
Methods: In this single-center, prospective, double-blind study, adults undergoing elective thoracic or thoracoabdo-
minal aortic replacement surgery involving cardiopulmonary bypass were randomized to intraoperative fibrinogen
concentrate (n¼ 29) or placebo (n¼ 32). Studymedicationwas given if patients had clinically relevant coagulopathic
bleeding,measuredby5-minutebleedingmass, after cardiopulmonarybypass removal, protamineadministration, and
surgical hemostasis. Fibrinogen concentrate dosing was individualized using the thromboelastometric FIBTEM test.
If bleeding continued, a standardized transfusionalgorithmwas followed. In theplacebogroup, all 32patients received
1 transfusion cycle of fresh-frozen plasma/platelets, and 30 patients required a second transfusion cycle; none of these
patients received any other procoagulant therapy. Change in bleeding rate after treatment was compared using t tests.
Results: Mean change in bleeding rate after fibrinogen concentrate was 48.3 g/5 min, compared with 0.4 g/5
min after placebo (P<.001),16.1 g/5min after 1 transfusion cycle (fresh-frozen plasma or platelets;P¼ .003),
and28.0 g/5min after 2 transfusion cycles (fresh-frozen plasma and platelets;P¼ .11). Reductions in bleeding
rate were greater for patients with higher bleeding rates before treatment, especially with fibrinogen concentrate.
Conclusions: FIBTEM-guided intraoperative hemostatic therapy with fibrinogen concentrate is more effective
than placebo in controlling coagulopathic bleeding during major aortic replacement surgery. Fibrinogen concen-
trate is also more effective than 1 cycle of fresh-frozen plasma/platelets and is more rapid than—and at least as
effective as—2 cycles of fresh-frozen plasma/platelets. (J Thorac Cardiovasc Surg 2013;145:S178-85)Complex cardiac surgery can be accompanied by excessive
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The Journal of Thoracic and Cardiovascular Surconsumption of coagulation factors. Impairment of coagu-
lation may be further aggravated by hypothermic circula-
tory arrest1 and coagulopathy associated with the use of
cardiopulmonary bypass (CPB).2,3 Volume replacement
therapy may also be required, potentially resulting in
dilutional coagulopathy.4,5 Failure to manage these
coagulopathies and control blood loss can increase the
risk of subsequent morbidity and mortality.6
Acquired hypofibrinogenemia is a common coagulop-
athy associated with cardiac surgery, and baseline plasma
fibrinogen levels have been reported to decrease by 34%
to 58% during CPB.7-9 Because fibrinogen is the
precursor to fibrin, low fibrinogen levels can compromise
fibrin-based clot formation. Fibrin clot quality, recorded
using the thromboelastometry-based FIBTEM test
(ROTEM device; TEM International, Munich, Germany),
has been shown to decrease by 38% to 52% during
CPB.10,11 Time spent on CPB is therefore an important
factor and typically greater for complex cardiac surgeries
accompanied by substantial blood loss than for
procedures such as coronary artery bypass graft surgery.
Low plasma fibrinogen levels in patients undergoing car-
diac surgery are associated with increased postoperative
blood loss.7,12-14 Consequently, fibrinogen replacementgery c March 2013
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
FC ¼ fibrinogen concentrate group
FFP ¼ fresh-frozen plasma
Drate ¼ change in the rate of bleeding
Rahe-Meyer et al Panel 4therapy targeting a high-normal level of plasma fibrinogen
and fibrin-based clot formation may be an important first
step in restoring hemostasis during major bleeding after
CPB. Fibrinogen replacement therapy may involve transfu-
sion with fresh-frozen plasma (FFP) or cryoprecipitate.
However, FFP has a low and variable concentration of
fibrinogen15 and cannot be used when targeting a high-
normal plasma fibrinogen level.8 Furthermore, the hemo-
static efficacy of FFP has been questioned.16,17
Cryoprecipitate has been withdrawn from many countries
because of safety concerns,18 and although it remains an op-
tion in some countries, it is not appropriate as first-line he-
mostatic therapy. Fibrinogen concentrate may be used for
fibrinogen replacement and, unlike cryoprecipitate, un-
dergoes purification and virus inactivation/removal steps
during manufacturing. Fibrinogen concentrate is widely
used for congenital fibrinogen deficiencies and reported to
be potentially effective in acquired hypofibrinogene-
mia.16,19 Clinical evidence from prospective randomized
trials is needed to demonstrate the efficacy of fibrinogen
concentrate in controlling perioperative bleeding.
Our group performed a double-blind, randomized,
placebo-controlled trial to investigate the efficacy of
goal-directed, FIBTEM-guided fibrinogen concentrate as
first-line hemostatic therapy during aortic replacement sur-
gery. To be included in the study, patients had to exhibit
clinically relevant bleeding before administration of fibrin-
ogen concentrate or placebo, determined by measurement
of the rate of coagulopathic bleeding after CPB discontin-
uation and reversal of heparin anticoagulation. Further
measurements of the rate of bleeding were recorded after
fibrinogen concentrate or placebo administration and again
after cycles of additional hemostatic therapy (transfusion
with FFP/platelets) for patients in the placebo group.
The main aim of this investigation was to examine changes
in the rate of bleeding recorded before and after adminis-
tration of fibrinogen concentrate or placebo to determine
whether fibrinogen concentrate is more effective than pla-
cebo in controlling coagulopathic bleeding (ie, achieves
a greater reduction in the rate of bleeding). Additional
analyses are presented that compare the reduction in the
rate of bleeding after fibrinogen concentrate infusion
with that achieved by transfusion of FFP or platelets in pa-
tients in the placebo group. Treatment with fibrinogen con-
centrate reduced average transfusion requirements for FFP,The Journal of Thoracic and Cardplatelets, and red blood cells, and increased the number of
patients avoiding transfusion altogether.20MATERIALS AND METHODS
Study Design, Patient Population, and Procedures
This study was conducted at Hannover Medical School, Germany, and
was approved by the local Ethics Committee and the German Regulatory
Authorities; it was conducted in accordancewith theDeclaration of Helsinki
andGoodClinical Practice. The studywas assigned Local Ethics Committee
reference code 4891M-mono, EudraCT trial number 2007-004612-31, and
Clinicaltrials.gov identifier number NCT00701142. Patients aged 18 years
or more and scheduled to undergo elective aortic replacement surgery with
CPB were screened for eligibility between June 2008 and April 2010. We
planned for 60 patients on the basis of a statistical power calculation for anal-
ysis of patients’ transfusion requirements.20 Eighty patients were enrolled
and randomized to fibrinogen concentrate (FC) or placebo groups by an un-
blinded pharmacist bound by a confidentiality agreement. Randomization
numbers were assigned sequentially, in a 1:1 ratio, with a block size of 4,
stratified by surgery type. Sixty-one patientswere then included in a prospec-
tive, randomized, placebo-controlled study after signed consent had been ob-
tained (Figure 1). Exclusion criteria included patients with congenital or
acquired coagulation disorders, previous surgery at the same site, stroke or
myocardial infarctionwithin 2months before surgery, anduse of aspirin, clo-
pidogrel, or vitamin K antagonists within 2 to 5 days before surgery. Patients
underwent 1 of 3 procedures: aortic valvewith root/ascending aorta replace-
ment (n¼ 21), aortic valvewith root/ascending aorta and aortic arch replace-
ment (n ¼ 22), or thoracoabdominal aortic replacement (n ¼ 18).
Intraoperative Measurement of the Rate of Bleeding
After CPBdiscontinuation, neutralization of heparin using protamine, and
surgical control of focal bleeding, the rate of coagulopathic bleeding was
measured to assess eligibility for fibrinogen concentrate placebo administra-
tion. Patients had receivednoprior procoagulant therapy. The rate of bleeding
was quantified bymeasuring 5-minute bleedingmass. Dry surgical cloths and
compresseswereweighed, applied to the surgical area for precisely5minutes,
and then weighed again. Because the density of blood is approximately 1060
g/L,21 1 g of recordedmass represents approximately 1 mL of lost blood.We
have previously used this approach to assess intraoperative bleeding during
aortic surgery.8,10 On the basis of experiences at Hannover Medical School,
bleeding in the range of 60 to 250 g/5 min (680-2800 mL/h), where
macrovascular bleeding is not evident, indicates coagulopathic bleeding of
the microvasculature that cannot be surgically controlled. Patients with
a rate of bleeding in this range were included in the study (Figure 1).
Administration of Hemostatic Therapies and Further
Assessment of Bleeding
Measurement of bleeding and administration of hemostatic intervention
were continuously alternating processes (Figure 2). In the 5 minutes after
the first measurement, patients with clinically relevant bleeding were in-
fused with fibrinogen concentrate (FC group, n = 29) or an equivalent vol-
ume of 0.9% saline (placebo group, n ¼ 32). Fibrinogen concentrate
dosing was guided by FIBTEM maximum clot firmness results, as de-
scribed previously.8-10 Medication was prepared by the unblinded
pharmacist, and opaque perfusion syringes were delivered to the
operating room labeled with subject and study identification numbers.
The content of each syringe (either 50 mL of 0.9% saline as placebo or
1 g fibrinogen concentrate dissolved in 50 mL water for injection) was
administered in less than 20 seconds. The median total dose was 8 g
(minimum 3 g, maximum 14 g). Anesthesiologists and surgical staff
were blinded to therapy. In the 5 minutes after infusion, the second
measurement of bleeding was recorded; if less than 60 g/5 min,
hemostasis was considered achieved, and surgery proceeded toiovascular Surgery c Volume 145, Number 3S S179
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FIGURE 1. CONSORT flow diagram of patient progression through this parallel, randomized trial. *Patients did not receive the allocated intervention
because the rate of bleeding was less than 60 g/5 min or more than 250 g/5 min, FIBTEMmaximum clot firmness was greater than the 22-mm target level,
or because there was a late decision not to proceed with aortic replacement surgery.
Panel 4 Rahe-Meyer et alcompletion. When the rate of bleeding remained 60 g or more/5 min,
patients were treated using a predefined transfusion algorithm: If platelet
count at removal of the aortic clamp was less than 100,000/mL, 2 units
of apheresis platelet concentrate were administered; for a platelet count
of 100,000/mL or more, 4 units of FFP were administered. During the 5
minutes after transfusion, the rate of bleeding was measured for a third
time and a second transfusion cycle was then administered to patients
still bleeding 60 g or more/5 min. Two units of platelets were given to
patients who received 4 units FFP in the first transfusion cycle, and vice
versa. The fourth measurement was recorded in the 5 minutes
immediately after this second transfusion cycle, and patients with
coagulopathic bleeding continued to receive further cycles of concurrent
transfusion with FFP and platelets. Because of the decreasing number of
patients requiring extended therapy, meaningful statistical analysis of
later interventions and their subsequent effects on bleeding could not beS180 The Journal of Thoracic and Cardiovascular Surperformed. Several patients in the FC group went on to receive FFP or
platelets after the second bleeding rate measurement. However, only the
first and second measurements of the rate of bleeding (ie, at baseline and
post–fibrinogen concentrate) are analyzed for patients in the FC group in
this report, because meaningful assessment of changes in the rate of bleed-
ing after FFP/platelet transfusions would be confounded by the initial
fibrinogen concentrate administration.
Statistical Analysis
To determine the hemostatic effects of fibrinogen concentrate and placebo,
the change in the rate of bleeding (Drate) from the first measurement (pre-infu-
sion) to the secondmeasurement (post-infusion)wascalculated (Figure2) forall
patients in both groups. All datawere normally distributed so theDrate for each
group is presented as mean (standard deviation). Individual Drate values were
compared between groups using an unpaired t test. The spread of Drate valuesgery c March 2013
CPB removed, heparin neutralized
with protamine, surgical control of
focal bleeding complete
Aortic replacement surgery performed on CPB
Continued hemostatic therapy and completion of surgery
Transfusion cycle 1
4 U FFP or 2 U platelets according
to predefined algorithm
Transfusion cycle 2
4 U FFP if platelets given in cycle 1
2 U platelets if FFP given in cycle 1
Measurement of rate of bleeding
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FIGURE 2. Sequence of intraoperative events illustrating the timing of measurements of the rate of bleeding and administration of hemostatic therapies,
and the time-points used to calculate changes in the rate of bleeding (Drate) after different hemostatic interventions. CPB, Cardiopulmonary bypass; FC,
fibrinogen concentrate; FFP, fresh-frozen plasma; FIBTEM, fibrin-based thromboelastometry test.
Rahe-Meyer et al Panel 4washigher for theFCgroup than for theplacebogroup; to allowfor this, aWelch
correction was used. This analysis was a prespecified efficacy end point.
Todetermine thehemostatic effectof1 cycleof transfusion (4unitsFFPor2
units platelets), theDrate from the secondmeasurement (pre-transfusion cycle
1) to the third measurement (post-transfusion cycle 1) of the rate of bleeding
was calculated. This calculation was performed using only the placebo group.
By using the individualDrate values calculated for 1 transfusion cycle, the he-
mostatic effects of fibrinogenconcentrateversus 1 transfusion cyclewere com-
pared as described for fibrinogen concentrate versus placebo. The hemostatic
effects of 1 transfusion cycleversus placebo (awithin-group comparison)were
compared using a paired t test.
To determine the hemostatic effect of 2 cycles of transfusion (total of 4
units FFP and 2 units platelets), the Drate from the second measurement
(pre-transfusion cycle 1) to the fourth measurement (post-transfusion cycle
2) of the rate of bleeding was calculated. This was performed for the 30 ofThe Journal of Thoracic and Card32 patients in the placebo group who received 2 cycles of transfusion; no
patients in the FC group were included. By using the individual Drate
values calculated for 2 transfusion cycles, the hemostatic effects of fibrin-
ogen concentrate versus 2 transfusion cycles were compared as described
for fibrinogen concentrate versus placebo. The hemostatic effects of 2
transfusion cycles versus placebo were compared using a paired t test.
Trend lines on graphs represent linear regressions performed using Micro-
soft Excel (Microsoft Corp, Redmond, Wash).RESULTS
Patient Demographics
Most patients were male (FC group, 66%; placebo
group, 78%), and there were no major differences iniovascular Surgery c Volume 145, Number 3S S181
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FIGURE 3. A, Individual patient data for changes in the rate of coagulopathic bleeding after treatment with placebo, 1 cycle of transfusion, 2 cycles of
transfusion, or fibrinogen concentrate. B, Changing trends in the rate of bleeding after treatment with placebo, 1 cycle of transfusion, 2 cycles of transfusion,
or fibrinogen concentrate. Grey dotted line, no effect.
Panel 4 Rahe-Meyer et almean age (59 vs 61 years), weight (88 vs 87 kg), body
mass index (28 vs 28 kg/m2), obesity (24% vs 22%), pre-
existing medical conditions, or type of operation that
would be expected to affect the results. Each group was
typical for patients undergoing aortic replacement
surgery.
Comparing the Hemostatic Effects of Fibrinogen
Concentrate Versus Placebo
Before treatment, each group had similar mean (stan-
dard deviation) baseline rates of coagulopathic bleeding:
placebo group, 121 (50) g/5 min; FC group, 116 (46) g/
5 min. This is visible in Figure 3, A, where the values
for the placebo and FC groups are comparably distributedS182 The Journal of Thoracic and Cardiovascular Suralong the x-axis. Thus, there were no obvious differences
in bleeding between the 2 groups before infusion of pla-
cebo or fibrinogen concentrate, which would be expected
to cause different hemostatic responses.
Mean Drate was assessed post-infusion. A negative
Drate value indicates a reduction in the rate of bleeding,
whereas a positive value indicates an increase (Figure 3).
Placebo treatment displayed a negligible effect on coagu-
lopathic bleeding, with the rate of bleeding increasing by
0.4 g/5 min (5 mL/h) (Table 1). After infusion with fi-
brinogen concentrate, the mean Drate indicated a reduction
in the rate of bleeding of 48 g/5 min (Table 1), approxi-
mately equivalent to 550 mL/h. More pronounced reduc-
tion in the rate of bleeding was typically observed forgery c March 2013
TABLE 1. Results of statistical analyses
Comparison
Treatment A Treatment B
Difference mean (95% CI) P valueN Drate mean (SD) N Drate mean (SD)
(A) FC vs (B) placebo 29 48.3 (48.6) 32 0.4 (15.1) 48.8 (67.9 to 29.6) <.001
(A) 1 cycle of FFP/platelets vs (B) placebo 32 16.1 (26.1) 32 0.4 (15.1) 16.6 (27.5 to 5.7) .004
(A) 2 cycles of FFP/platelets vs (B) placebo 30 28.0 (46.6) 30 1.7 (14.8) 29.7 (47.1 to 12.3) .002
(A) FC vs (B) 1 cycle of FFP/platelets 29 48.3 (48.6) 32 16.1 (26.1) 32.2 (52.7 to 11.2) .003
(A) FC vs (B) 2 cycles of FFP/platelets 29 48.3 (48.6) 30 28.0 (46.6) 20.3 (45.1 to 4.6) .11
Statistically significant P values are in bold.Drate, Change in the rate of bleeding; SD, standard deviation; CI, confidence interval; FC, fibrinogen concentrate; FFP, fresh-frozen
plasma.
Rahe-Meyer et al Panel 4patients exhibiting a higher rate of bleeding before fibrin-
ogen concentrate infusion. Statistical comparison con-
firmed that fibrinogen concentrate was more effective
than placebo for controlling intraoperative bleeding
(P<.001, Table 1).
Comparing the Hemostatic Effects of 1 Cycle of
Transfusion (Fresh-Frozen Plasma or Platelets)
Versus Placebo
All patients in the placebo group (32/32) received at least 1
cycle of transfusionwith 4 units FFPor 2 units platelet concen-
trate. Because placebo infusion had little effect on the rate of
bleeding, the hemostatic effect of FFP/platelet transfusion
could be assessed by monitoring subsequent changes in the
rate of bleeding.As a baseline for determiningDrate after 1 cy-
cle of transfusion, the secondmeasurement of the rate of bleed-
ing was used (Figure 2). This valuewas recorded immediately
before FFP/platelet transfusion, and themean (standard devia-
tion) rate of bleeding for the placebo group at this timewas 122
(55) g/5 min, which was comparable with the rate of bleeding
observed before placebo infusion. After FFP/platelets transfu-
sion, there was an overall decrease in the rate of bleeding
(Figure 3, B). The meanDrate (Table 1) indicated that 1 trans-
fusion cycle reduced the rate of coagulopathic bleeding by 16
g/5min, equivalent to approximately180mL/h.This reduction
was significant compared with placebo (P ¼ .004, Table 1).
Comparing the Hemostatic Effects of 2 Cycles of
Transfusion (Fresh-Frozen Plasma and Platelets)
Versus Placebo
In the placebo group, 30 of 32 patients received a second
cycle of transfusion, in which patients were given which-
ever therapy was not received in the first cycle. Conse-
quently, all 30 patients undergoing 2 cycles of transfusion
received a total of 4 units FFP and 2 units platelets. The he-
mostatic effect of this combination was assessed by calcu-
lating the Drate between the measurements made before
any transfusion (second measurement) and after 2 cycles
of transfusion (fourth measurement). Transfusion with 4
units FFP plus 2 units platelets led to an overall reduction
in the rate of bleeding of 28 g/5 min (Figure 3, B), equiva-
lent to approximately 320 mL/h. This reduction was also
significant compared with placebo (P ¼ .002, Table 1).The Journal of Thoracic and CardComparing the Hemostatic Effects of Fibrinogen
Concentrate Versus 1 Cycle of Transfusion (Fresh-
Frozen Plasma or Platelets)
Although the first cycle of transfusion had a positive he-
mostatic effect, statistical comparison revealed that the re-
duction in the rate of bleeding observed after transfusion
with FFP or platelets was significantly less than the reduc-
tion in the rate of bleeding observed after fibrinogen con-
centrate infusion (P ¼ .003, Table 1).
Comparing the Hemostatic Effects of Fibrinogen
Concentrate Versus 2 Cycles of Transfusion (Fresh-
Frozen Plasma and Platelets)
The decrease in the rate of bleeding after 2 cycles
of transfusion (28 g/5 min, 320 mL/h) was also not as
great as that seen after treatment with fibrinogen concen-
trate (48 g/5 min, 550 mL/h); however, this difference
did not reach statistical significance (P ¼ .11, Table 1).
DISCUSSION
In this single-center, prospective, randomized, double-
blind, placebo-controlled study, we used 5-minute bleeding
mass to accurately quantify the rate of coagulopathic bleed-
ing in patients undergoing major aortic replacement surgery.
This unique tool has never before been used in a prospective,
randomized study. We successfully used 5-minute bleeding
mass as a marker of the beginning (60 g/5 min) and end
(<60 g/5 min) of clinically relevant coagulopathic bleeding
and of the patient’s response to hemostatic therapy, avoiding
the need to rely on subjectivemeasures. Our results show that
FIBTEM-guided intraoperative hemostatic monotherapy
with fibrinogen concentrate is more effective than placebo,
4 units FFP, or 2 units platelets, and is at least as effective
as 4units FFPplus 2units platelets in reducing the rate of coa-
gulopathic bleeding duringmajor aortic replacement surgery.
That FIBTEM-guided fibrinogen concentrate as first-line
hemostatic therapy led to a significant reduction in the rate
of bleeding explains why patients who received fibrinogen
concentrate required fewer transfusions with allogeneic
blood products than patients who received placebo.20 The
difference in mean values suggests that fibrinogen concen-
trate may be more effective than even 2 transfusion cycles
of FFP/platelets. It will be interesting to see whether thisiovascular Surgery c Volume 145, Number 3S S183
Panel 4 Rahe-Meyer et alis confirmed in the Phase III REPLACE study
(NCT01475669). Of note is that 4 units FFP plus 2 units
platelets takes substantially longer to administer than 1 in-
fusion with fibrinogen concentrate, and this is an important
consideration when control of acute bleeding is urgently re-
quired. Whereas allogeneic blood products must be cross-
matched and thawed, and large volumes given, fibrinogen
concentrate can be stored at room temperature, rapidly re-
constituted, and infused as a smaller volume. In addition, fi-
brinogen concentrate avoids many of the safety issues
associated with allogeneic blood products, such as
transfusion-related acute lung injury, transfusion-
associated circulatory overload, acute respiratory distress
syndrome, and transfusion-related immunomodulation.22-24
The benefits of targeted, individualized dosing of fibrin-
ogen concentrate are evident in that changes in the rate of
bleeding were more pronounced for patients with a high
initial rate. This was evident to a lesser degree after trans-
fusion with FFP/platelets, where dosing was fixed and not
tailored to the individual patient. Consistent with previous
studies in cardiac surgery8,10,25 and trauma,26 our findings
demonstrate the benefit of using a target FIBTEM maxi-
mum clot firmness value to guide appropriate dosing of fi-
brinogen concentrate. This ‘‘theragnostic’’ approach
integrates rapid diagnostic testing with drug therapy, en-
suring that fibrinogen concentrate is administered and
dosed in line with patients’ actual needs. Two systematic
reviews, which included several prospective studies in car-
diovascular surgery, concluded that fibrinogen concentrate
therapy could increase clot firmness and decrease transfu-
sion requirements, blood loss, and postoperative drainage
volumes.16,19
Study Limitations
A limitation of the present analyses is that different time-
points were used as the baseline from which to measure the
hemostatic effect of treatment with FFP/platelets than were
used when measuring the effects of fibrinogen concentrate
and placebo; however, we did ensure before performing
the comparisons that the baseline values were comparable
for both groups and at both time-points. We cannot rule
out the possibility of selection bias in using ‘‘nonre-
sponders’’ from the placebo group for the assessment of 2
transfusion cycles (FFP and platelets). However, this is ex-
pected to have had little impact, because the majority (30/
32, 94%) of patients in the placebo group were ‘‘nonre-
sponders’’ (ie, went on to receive a second cycle of trans-
fusion). In addition, only comparisons of Drate after
administration of fibrinogen concentrate or placebo repre-
sent comparisons between prespecified efficacy end points.
Comparisons of placebo or fibrinogen concentrate versus 1
or 2 cycles of transfusion are exploratory analyses that war-
rant further prospective investigation. Although 5-minute
bleeding mass as a tool to quantify the rate of intraoperativeS184 The Journal of Thoracic and Cardiovascular Surcoagulopathic bleeding has not been used in a prospective,
randomized trial, our group has successfully used it in small
prospective aortic surgery studies.8,10 The present study
provides further evidence that this method yields accurate
and reproducible measurements.
CONCLUSIONS
A single, targeted dose of fibrinogen concentrate after dis-
continuation of CPB controls coagulopathic bleeding during
aortic surgerymore effectively than placebo or a standardized
treatment algorithm of 4 units FFP or 2 units apheresis plate-
lets. Fibrinogen concentrate also enables more rapid and at
least as effective control of intraoperative bleeding when
comparedwith transfusionof4units FFPand2units platelets.
These findings support the use of goal-directed, FIBTEM-
guided fibrinogen concentrate as a rapid and efficacious
first-line hemostatic therapy in patients with coagulopathic
bleeding undergoing major aortic replacement surgery.
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